INAB, US45674E2081

IN8bio stock fell 6.33 percent to USD 1.11 on October 16, 2026

Published on 10/17/2026 at 20:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IN8bio held USD 17.96 million in cash on June 30, 2026. IN8bio stock closed at USD 1.11 on October 16, 2026, down 6.33 percent on Nasdaq.

Cash and valuation points

On October 16, 2026, Nasdaq trading left IN8bio stock down 6.33 percent.
IN8bio held USD 17.96 million in cash and equivalents on June 30, 2026.
IN8bio stock closed at USD 1.11 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 6.33 percent versus the prior close.
IN8bio is scheduled to report third-quarter results on November 5, 2026.

INAB, US45674E2081, Illustration mit AI erstellt.

IN8bio stock fell 6.33 percent on Nasdaq in its latest completed session on October 16, 2026. The company held USD 17.96 million in cash and equivalents at June 30, 2026. IN8bio stock closed at USD 1.11 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 6.33 percent versus the prior close.

Cash position at June 30

Cash and equivalents declined from USD 21.94 million at March 31, 2026, to USD 17.96 million at June 30, 2026. That USD 3.98 million sequential reduction gives the balance sheet a more concrete role in assessing the company alongside its clinical pipeline.

IN8bio describes its business as the development of gamma-delta T-cell therapies for cancer and autoimmune diseases. The company lists New York City as its location and Birmingham, Alabama, as a primary scientific operations site.

Price range and trading activity

IN8bio traded between USD 1.06 and USD 1.19 during the October 16, 2026 session, with volume of 31,699 shares against an average volume of 54,792. Its 52-week range was USD 0.88 to USD 2.73, placing the closing price 26.14 percent above the low and 59.34 percent below the high.

Valuation and November date

The company had a market capitalization of USD 10.9 million as of October 16, 2026. Its price-to-earnings ratio was minus 0.59. MarketBeat lists November 5, 2026, as the estimated date for the third-quarter earnings release, before the market opens.

Comparison with peers

IN8bio (Nasdaq, USD): minus 6.33 percent, P/E minus 0.59, market capitalization USD 10.9 million.
Keros Therapeutics (Nasdaq, USD): minus 3.96 percent, P/E minus 3.31, market capitalization USD 211.4 million.
Dare Bioscience (Nasdaq, USD): minus 2.08 percent, P/E minus 0.92, market capitalization USD 10.9 million.

Closing price and trading range

The October 16, 2026 close of USD 1.11 leaves IN8bio below the midpoint of its USD 0.88 to USD 2.73 52-week range. The next scheduled earnings date is November 5, 2026.